For a century, insulin has been the only drug available to type 1 diabetics. Now a raft of novel drugs are coming through the pipeline. Michael Eisenstein reports.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Fischer, B. et al. Expert Opin. Biol. Ther. 2, 265–272 (2010).
Couri, C.E. et al. J. Am. Med. Assoc. 301, 1573–1579 (2009).
Tang, Q. et al. J. Exp. Med. 199, 1455–1465 (2004).
Suarez-Pinzon, W.L. et al. Cell Transplant. 17, 631–640 (2008).
Thorel, F. et al. Nature 464, 1149–1154 (2010).
Skyler, J.S. et al. Diabetes Care 28, 1068–1076 (2005).
Malecki, M. & Klusacek, M. Biosimilars: ESAs, Insulins, and Human Growth Hormones (Decision Resources, 2009). <http://decisionresources.com/Products-and-Services/Report?r=drrppl0309>
El-Khatib, F.H. et al. Sci. Transl. Med. 2, 27ra27 (2010).
About this article
Cite this article
Eisenstein, M. More than insulin. Nat Biotechnol 29, 782–785 (2011). https://doi.org/10.1038/nbt.1967
This article is cited by
Nature Biotechnology (2012)